Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Director's Dealings

18th Mar 2009 10:23

RNS Number : 0501P
ABCAM Plc
18 March 2009
 



For immediate release

18 March 2009

ABCAM PLC

("Abcam" or "the Company")

Director's Dealings 

Cambridge UK, 18 March 2009: Abcam plc, the rapidly growing bioscience company that markets antibodies via its own online catalogue, announces that, in order to meet institutional demand, on 17 March 2009 David Cleevely Non-Executive Chairman, sold 800,000 Ordinary Shares of 1p each in the Company at a price of 575p per share. Following the disposal Dr Cleevely has a beneficial interest in 2,559,760 shares, representing approximately 7.2% of the Company's issued share capital.

 

For further information please contact:

Abcam

+ 44 (0) 1223 696000

Jonathan Milner, Chief Executive Officer

Jeffrey Iliffe, Chief Financial Officer

www.abcam.com

Numis Securities

+ 44 (0) 20 7260 1000

Michael Meade Nick Westlake - Nominated Adviser

James Black - Corporate Broking

Buchanan Communications

+ 44 (0) 20 7466 5000

Mark Court / Mary-Jane Johnson / Stasa Filiplic

Notes for editors:

About Abcam plc

Abcam is a producer and distributor of research-grade antibodies headquartered in CambridgeUK, with a US office located in CambridgeMassachusetts and a Japanese office in Tokyo. Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company produces and distributes its own and third party produced antibodies to academic and commercial users throughout the world with product information provided and ordering available through the Company's website, www.abcam.com. The antibodies are sold under the Abcam brand name. The Company's vision is to build the largest online antibody resource in the world while also ensuring that the antibodies are of high quality and commercially viable. Abcam now has an online catalogue of over 50,000 products, most of which are antibodies, from over 250 suppliers supported by up-to-date and detailed technical data sheets, which are created by the Company. The Company currently employs 225 staff in its three operating companies.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSGUUPPWUPBGUR

Related Shares:

ABC.L
FTSE 100 Latest
Value8,275.66
Change0.00